EVALUATION OF BIOCHEMICAL PARAMETERS IN BLOOD PLASMA WITH LONG-TERM OPIOID THERAPY AND AFTER OPIOID WITHDRAWAL

Vilkhova I.V.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

Long-term use of opioids in the treatment of chronic pain leads to toxic effects on a number of organs. Changes in the biochemical parameters of the functional state of the kidney with the use of various opioid drugs have been studied, however, there is little data in the literature on the dynamics of changes in renal markers indicating renal dysfunction after opioid withdrawal. The aim of the study was to establish some biochemical parameters of rat serum with long-term therapeutic doses of nalbuphine and in the late stages of drug withdrawal. The study was performed on 45 white sexually mature male rats weighing 180–260 g, which were injected intravenously for 70 days with Nalbuphine (Nalbuphine injection 20 mg). Serum total protein, urea, creatinine, calcium and phosphorus were determined. The obtained data were tested for the normality of the distribution using the coefficients of asymmetry and excess, as well as using the Shapiro-Wilk test (confidence level p<0.1). Non-parametric Kraskel-Wallis test H followed by a posteriori analysis using Dunn’s test was used to determine the statistical significance of the difference between the data in multiple comparisons. Statistical calculations were performed using RStudio v. 1.1.442 and R Commander v.2.4–4. The data suggest that the use of therapeutic doses of nalbuphine for six weeks and after withdrawal does not lead to changes in rat serum protein. The highest value of serum creatinine is observed after six weeks of nalbuphine administration. With further administration of the drug until the tenth week, the serum creatinine level is significantlyreduced, as with the withdrawal of nalbuphine, although it is almost twice as high as the control. Significant increase in urea is observed after six weeks of nalbuphine use, and the peak value – after ten weeks of nalbuphine administration. After drug withdrawal, serum urea is reduced to the level of control group. Thus, the data of the study indicate that longterm use of nalbuphine leads to an increase in serum urea and creatinine, which are markers of impaired renal nitrogen function and probable damage to the renal corpuscle, and drug withdrawal leads to partial recovery of this function. Changes in serum calcium and phosphorus indicate impaired renal reabsorption function and nephron convoluted tubular damage with ten weeks of nalbuphine administration and normal function after opioid withdrawal from the sixth week.

kidney, nephron, biochemical parameters, opioids.

1. Nuckols TK, Anderson L, Popescu I, Diamant AL, Doyle B, Di Capua P, et al. Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med. 2014;160:38–47.
2. Novick T, Kuo YF, Raji MA, Chen NW, Hasan H, Goodwin JS. Trends in opioid prescriptions among part D medicare recipients from 2007 to 2012. Am.J. Med. 2016;129:21–30.
3. Barbosa-Leiker C, McPherson S, Daratha K, Alicic R, Short R, Dieter B, et al. Association between prescription opioid use and biomarkers of kidney disease in US adults. Kidney Blood Press Res. 2016;41:365–373. DOI: 10.1159/000443436.
4. Coluzzi F, Caputi FF, Billeci D, Pastore AL, Candeletti S, Rocco M, et al. Safe Use of Opioids in Chronic Kidney Disease and Hemodialysis Patients: Tips and Tricks for Non-Pain Specialists. Ther Clin Risk Manag. 2020;16:821–837. DOI: https://doi. org/10.2147/TCRM.S 262843.
5. Pham PC, Khaing K, Sievers TM, Pham PM, Miller JM, Pham SV, et al. 2017 update on pain management in patients with chronic kidney disease. Clin. Kidney J. 2017;10:688–697. DOI: 10.1093/ckj/sfx080.
6. Sumathi T, Niranjali Devaraj S. Effect of Bacopa monniera on liver and kidney toxicity in chronic use of opioids. Phytomedicine 2009;16(10):897–903. DOI: 10.1016/j.phymed.2009.03.005.
7. Vilkhova I, Mateshuk-Vatseba L, Logash M, Kantser O. Biochemical parameters of the rat’s blood under chronic opioid exposure World of Medicine and Biology 2021;3(77):199–203. DOI: 10.26724/2079–8334–2021–3–77–199–203.
8. Atici S, Cinel I, Cinel L, Doruk N, Eskandari G, Oral U. Liver and kidney toxicity in chronic use of opioids: an experimental long term treatment model. J Biosci. 2005 Mar;30(2):245–52. DOI: 10.1007/BF02703705.
9. Hassan R, Pike See C, Sreenivasan S, Mansor SM, Müller CP, Hassan Z. Mitragynine Attenuates Morphine Withdrawal Effects in Rats – A Comparison With Methadone and Buprenorphine. Front. Psychiatry. 2020;11:411. DOI: 10.3389/fpsyt.2020.00411.
10. Afarinesh MR, Haghpanah T, Divsalar K, Dehyadegary E, Shaikh-Aleslami A, Mahmoodi M. Changes in serum biochemical factors associated with opium addiction after addiction desertion. Addict Health. 2014;6(3–4):138–45.
11. Paltov YV, Fik VB, Vilkhova IV, Onysʹko RM, Fitʹkalo OS, Kryvko YUYA, vynakhidnyky; L’vivs’kyj nacional’nyj medychnyj universytet imeni Danyla Galyc’kogo, patentovlasnyk. Sposib modeljuvannja hronichnogo opioi’dnogo vplyvu. Patent Ukrainy № 76565. 2013 Sich 10. [in Ukrainian].
12. Zupanets IA, Mysyureva SV, Propysnova VV. Klinicheskaya laboratornaya diagnostika: metody issledovaniya. Khar’kov; 2005. 200 s. [in Russian].

«Bulletin of problems biology and medicine» Issue 2 Part 1 (164), 2022 year, 126-134 pages, index UDK 615.212.7:616.15–071

10.29254/2077-4214-2022-2-1-164-126-134